Cocrystal Pharma Inc
8CC
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.30 | 50.20 | 0.55% |
| CAC 40 | 8,358.76 | 3.33 | -0.04% |
| DAX 40 | 25,405.34 | 143.70 | 0.57% |
| Dow JONES (US) | 49,590.20 | 86.13 | 0.17% |
| FTSE 100 | 10,140.70 | 16.10 | 0.16% |
| HKSE | 26,953.90 | 345.42 | 1.30% |
| NASDAQ | 23,733.90 | 62.56 | 0.26% |
| Nikkei 225 | 53,540.60 | 1,600.71 | 3.08% |
| NZX 50 Index | 13,654.07 | 29.22 | -0.21% |
| S&P 500 | 6,977.27 | 10.99 | 0.16% |
| S&P/ASX 200 | 8,847.50 | 56.20 | 0.64% |
| SSE Composite Index | 4,168.16 | 2.87 | 0.07% |